China approves Sinovac vaccine World Health awaits assessment – post today around the world

China approves Sinovac vaccine World health awaits

On 07 February 2021 at 10:13 a.m.

–

China green light for Sinovac’s ‘COVID-19’ vaccine on market As world health reveals Two ‘Chinese vaccines’ under high evaluation

News agencyXinhuaIt is reported that Sinovac Biotech Co., Ltd. (Sinovac Biotech) revealed that the China National Medical Supplies Administration (NMPA) approved the sale of CoronaVac vaccine against the novel coronavirus disease (COVID-19). 19) of the company in the market conditionally On last Friday (Feb. 5)

Such vaccine It is produced by Sinovac Life Sciences Co., Ltd. (Sinovac Life Sciences) in Beijing. Capital of china Sinovac Biotech, a subsidiary of Sinovac, passed an emergency approval in China in June. It has been applied in emergencies to certain vulnerable populations in the country since last July.

Meanwhile, since January 2021, countries around the world such as Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay and Laos have continued to approve the domestic emergency use of Sinovac’s vaccine.

A statement on the Sinovac Biotech website states that the above countries accept vaccine clinical trials. It is believed that there is a clear feature in reducing medical treatment. Hospitalization Critically ill cases And deaths due to COVID-19 It is also of great importance to the prevention and control of pandemic.

Sinovac Life Sciences filed for the conditional release of the CoronaVac vaccine on the market on Feb 3, and it is approved. This is because the vaccine has been under two months of a Phase III clinical trial abroad.

The office requests that the company continue to conduct relevant clinical trials. Follow the terms and conditions And submit a follow-up to the research results within the deadline

“We hope to provide a safer and more effective vaccine as soon as possible. And help control COVID-19 From increasing vaccination rates To bolster social and economic development back to normalcy, ”said Yun Weitong, president and CEO of Sinovac Biotech.

The company stated that the vaccination process was divided into 2 doses, which were spaced 14-28 days, with each dose of 0.5 ml.

News agencyXinhuaAlso reported on Friday (February 5) Marie Angela Simao, assistant director general of the World Health Organization (WHO) for access to drugs, vaccines and pharmaceuticals. Two Chinese vaccines are now in a “advanced” evaluation process by the Organization for Emergency Usage Listings (EUL).

Simau announced that the vaccine produced by Sinovac and Sinopharm is one of four vaccines under advanced approval. By a group of experts from the organization They are already in China and they “will begin an investigation next week” as they are currently in quarantine.

Experts in China could get China’s vaccine to be approved in the shortest time. Because the documents published on the website of the Organization It states that Sinovac and Sinofarm vaccines have undergone multiple Phase III trials.

Requesting to be listed in emergency use Which is a new vaccine licensing process by the Organization It is important to many applicants for approval. In particular, to pass and be part of the COVAX Facility (COVAX Facility), an international initiative led by the Organization. For access to the COVID-19 vaccine Effectively and equally

Simao said there is currently only Pfizer-Bion Tech vaccine. (Pfizer-BioNTech) certified for emergency use by the Organization Two other vaccines, Britain’s AstraZeneca and South Korea’s SK Bioscience, are also being evaluated.

Many countries have started vaccination programs that have already been approved for their citizens. Amid the struggle to stop the pandemic around the world

Information from the organization A total of 238 COVID-19 vaccines are currently in development globally, with 63 vaccines in clinical trials in countries including Germany, China and Russia. UK and US

Thanks to the news content from Xinhua News Agency.

– .